Clinical trials: Hepatitis B and Hepatitis C
Indolent Lymphoma
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
We and other investigators have revealed an association between Hepatitis C virus (HCV) seropositivity and an increased risk of developing marginal zone B-cell lymphoma (MZ), lymphoplasmacytic lymphoma (LPL, also known as…
- Trial name
- NCT03261349
- Testing
- Ledipasvir and sofosbuvir
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
HIV Infections, Hepatitis B
Pilot Study of HIV and Hepatitis B and C Screening in Surgery
The purpose of the OPDEP pilot study is to assess the feasibility of implementing a pre-operative HIV / HCV / HBV screening proposal for all persons over 18 years of age and refer for surgical intervention under general…
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C
- Trial name
- OPDEP (NCT03088995)
- Testing
- Pilot study
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HBV, HCV
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed.
- Conditions
- HBV, HCV, HDV, Coinfection
- Trial name
- HEAL-S (NCT06834178)
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Vanessa Stadlbauer-Koellner, MD
HBV/HCV Co-infection
A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection
This is an open label, randomized-controlled, comparative trial. HBV and HCV dually infected patients with negative hepatitis B e antigen (HBeAg) were enrolled in the study.
- Trial name
- NCT02339337
- Testing
- Abbreviation of treatment duration
- Volunteers
- 203 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis C
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
This study is being done to evaluate the efficacy and safety of the drug combination grazoprevir (GZR; MK-5172) + elbasvir (EBR; MK-8742) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection and…
- Trial name
- NCT02115321
- Testing
- Grazoprevir, Elbasvir, MK-5172A
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Hepatitis B
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.
- Conditions
- Hepatitis C, Hepatitis B, Liver Cirrhoses
- Trial name
- NCT03620474
- Testing
- PRI-724
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Kiminori Kimura, MD
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus
This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection.
- Conditions
- Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, HIV Infections
- Trial name
- NCT00499434
- Where
- Brazil
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV Infections, Sexually Transmitted Infection
User-friendly HIV Testing and Counseling Services
Multicenter cohort study of individuals reporting behavioral risks of HIV acquisition, recruited among those presenting for testing for HIV and other sexually transmitted infections.
- Conditions
- HIV Infections, Sexually Transmitted Infection, Hepatitis B, Chronic, Hepatitis C
- Trial name
- NCT04585165
- Where
- 6 sites in Thailand
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Human Immunodeficiency Virus, Hepatitis B
Notification of Donors With Positive Microbiology Markers
Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Human T-lymphotropic Virus I & II
- Trial name
- NCT01050881
- Where
- United Kingdom
- Volunteers
- 217 people
- Sponsor
- NHS Blood and Transplant
Liver Cirrhosis, Chronic Hepatitis C
Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States veterans. Cirrhosis is associated with impaired antibody responses and increased risk of bacterial infections.
- Trial name
- NCT01951209
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- David E. Kaplan, MD MSc
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and…
- Trial name
- D-LITE (NCT01309932)
- Testing
- Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV)
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Iron Overload, Metabolic Syndrome X
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Iron excess is increasingly regarded as an important cofactor in the morbidity attributed to many disorders. Assessment of body iron stores by measurement of serum ferritin concentrations has poor specificity and the most…
- Conditions
- Iron Overload, Metabolic Syndrome X, Hepatitis B, Hepatitis C
- Trial name
- SURFER (NCT00401336)
- Testing
- Magnetic resonance imaging multiecho gradient-echo sequence
- Where
- 10 sites in France, Spain
- Volunteers
- 250 people
- Sponsor
- Rennes University Hospital
Hepatitis B, Hepatitis C
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Background: Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C.
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Trial name
- NCT01350648
- Where
- 2 sites in United States
- Volunteers
- 569 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis B， Chronic, Hepatitis C
The HOPE Study: Characterizing Patients With Hepatitis B and C
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C.
- Trial name
- NCT02995252
- Testing
- Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatitis C and B VIRUS Screening, Awareness and Behavior Assessment and Evaluation for All Inhabitants Above Twelve Years of Al Othmaneya Village
Effect of Implementation Of Outreach Behavioral Change Program for HCV Elimination
Elimination of hepatitis C virus (HCV) is the process of stopping sustained transmission of viral hepatitis, reducing its incidence to zero and providing access to safe, affordable and effective treatment and care for everyone.
- Trial name
- NCT03415334
- Testing
- behavioral development for change
- Volunteers
- 3,575 people, healthy volunteers welcome
- Sponsor
- National Research Centre, Egypt
Hepatitis, Hepatitis B
Crowdsourcing to Promote HBV and HCV Testing in China
This is an online randomized controlled trial (RCT) comparing men who have sex with men (MSM) exposed to a crowdsourced intervention to MSM who did not receive the intervention to determine the effect on Hepatitis B Virus (HBV)…
- Conditions
- Hepatitis, Hepatitis B, Hepatitis C
- Trial name
- NCT03482388
- Testing
- Crowdsourced materials, Control
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cirrhosis, Hepatitis B
FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
This study will examine the effectiveness of the FibroScan device in differentiating fibrosis in patients with hepatitis B and C.
- Conditions
- Cirrhosis, Hepatitis B, Hepatitis C
- Trial name
- NCT00125762
- Testing
- FibroScan
- Where
- 3 sites in United States
- Volunteers
- 907 people
- Sponsor
- Afdhal, Nezam, M.D.
HIV Infections, Hepatitis C Virus
Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
This pilot study aims to study gut B cells in HCV+HIV+, HCV+HIV-, HCV-HIV+, and HCV-HIV- volunteers. Volunteers will undergo a screening blood draw and flexible sigmoidoscopy with biopsy.
- Trial name
- NCT01040039
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Hepatitis B, Chronic, Adults
Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana
In South America, the prevalence of HBV is variable but high (> 8%) in the Amazon basin. In some areas, a third of HBsAg carriers are also infected with HDV, a major comorbidity factor.
- Trial name
- NCT04886102
- Testing
- An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital
- Where
- French Guiana
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier de Cayenne